Please login to the form below

OLED Medical Technology Saving Patient’s Sight During COVID-19 Pandemic

North East MedTech company secures investment agreement with Japanese tech giant

UK based PolyPhotonix haveagreed on OLED panel supply with Tohoku Pioneer Corporation, a consolidated subsidiary of Japanese tech giant Pioneer Corporation to ensure that diabetic patients at risk of losing their sight can continue to receive treatment during the COVID-19 pandemic.

The company’s OLED Business Unit will provide PolyPhotonix with state-of the-art OLED panels, as a light source that will be integrated into their Noctura 400 sleep mask used to treat Diabetic Retinopathy. The Noctura 400 sleep mask is an innovative non-invasive homecare monitored treatment for the most common cause of blindness in the western world.

Diabetic Retinopathy is a complication of diabetes caused by high blood sugar levels damaging the back of the eye, which can cause blindness if left untreated. The sleep mask designed to be worn at night, delivers a precise dose of light therapy during a patient’s normal hours of sleep in a home setting. The treatment reduces and reverses the effects of Diabetic Retinopathy.

In the UK, diabetes is the second most common underlying condition among COVID-19 patients who have died, of which 35% had the illness. Government advice is that patients in high risk categories should not go to hospital.

This means that patients previously receiving hospital treatment for diabetic eye disease are risking their sight, as many clinics have been cancelled due to the pandemic. Unlike other treatments such as laser intervention or eye injections, the Noctura 400 sleep mask can be used remotely in the patient’s home and doesn’t require a hospital visit.

The Noctura 400 treatment delivers proven results, with 94% of patients in a recent UK National Health Service hospital evaluation experiencing stabilisation and improvement in their condition after using the sleep mask. Following the success of Noctura 400 in UK, PolyPhotonix has plans to break into the Japanese market by taking the device through its regulatory approval system.

Richard Kirk, Chief Executive of PolyPhotonix says, “We are delighted to be working with Tohoku Pioneer who will be supporting our OLED requirements for Noctura 400 global volume growth’’. Together we can continue to save people’s sight during and after the pandemic. Current treatments for diabetic retinopathy are expensive, take up clinician’s time and require regular hospital visits. Our sleep mask can be used by patients at home, reducing the pressure on frontline hospital services and delivering cost savings.”

Masatoshi Yamaki, Director for Organic EL Business at Tohoku Pioneer, says, "Tohoku Pioneer will supply state-of-the-art OLED panels to be the light source in the Noctura 400, PolyPhotonix's sleep mask to treat diabetic retinopathy. We hope the use of our OLED panels in PolyPhotonix’s sleep mask, Noctura 400, will contribute to the treatment of people with this condition."

14th October 2020



Company Details

Onyx Health


Generator Studios, Trafalgar Street
Walker Road
Newcastle Upon Tyne
United Kingdom

Latest content on this profile

Onyx Health Expands with Two New Appointments
Newcastle-based creative agency Onyx Health has continued to grow and expand with the dual appointments of Rosie Thompson as Account Manager and Modupe Ayeni as a Medical Writer
Onyx Health
Sight-saving MedTech sleep mask could save the NHS multimillions
MedTech company PolyPhotonix has had its innovative diabetes sleep mask adopted in the NHS for the first time
Onyx Health
Onyx Health Goes for International Growth with New Managing Director
Onyx Health has announced the appointment of Trevor Pill as their new Managing Director. He will be taking over the day-to-day running of the agency from owner and founder Karen Winterhalter, who originally set up the agency in 2003.
Onyx Health
Onyx Health Expands with Two New Digital Appointments
Onyx Health has expanded its digital content team with the appointments of Hope Johnston as Digital Content Manager and Jordan Carr as Social Media Executive.
Onyx Health
Onyx Health Joins Forces with Rare Disease Specialists Actigen
Onyx Health will be working with Actigen to raise awareness of their innovative clinical trial work in rare diseases and the need to develop new treatment solutions.
Onyx Health
Onyx Health Announces a "Double Hatrick" of New Appointments
Onyx Health continues to expand with six new appointments to its creative and communication teams, due to increased growth in its international client portfolio work.
Onyx Health